Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Who Should Be Responsible for Relief of Financial Toxicity?
Symington BE, Abdel Karim NF, Kenney LB, Cole SM, Crawley MA, Kaur GNMN, Sullivan JE. Symington BE, et al. Among authors: cole sm. JCO Oncol Pract. 2022 Apr;18(4):311-312. doi: 10.1200/OP.21.00885. Epub 2022 Mar 10. JCO Oncol Pract. 2022. PMID: 35271296 No abstract available.
Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma.
Schoenhals JE, Mohamad O, Christie A, Zhang Y, Li D, Singla N, Bowman I, Arafat W, Hammers H, Courtney K, Cole S, Bagrodia A, Margulis V, Desai N, Garant A, Choy H, Timmerman R, Brugarolas J, Hannan R. Schoenhals JE, et al. Adv Radiat Oncol. 2021 May 26;6(5):100692. doi: 10.1016/j.adro.2021.100692. eCollection 2021 Sep-Oct. Adv Radiat Oncol. 2021. PMID: 34646963 Free PMC article.
Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R, Christensen M, Christie A, Garant A, Pedrosa I, Robles L, Mannala S, Wang C, Hammers H, Arafat W, Courtney K, Bowman IA, Sher D, Ahn C, Cole S, Choy H, Timmerman R, Brugarolas J. Hannan R, et al. Eur Urol Oncol. 2022 Dec;5(6):695-703. doi: 10.1016/j.euo.2022.06.008. Epub 2022 Aug 16. Eur Urol Oncol. 2022. PMID: 35985982 Free PMC article.
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy.
Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, Woo B, Li-Ning-Tapia E, Hahn NM, Carducci MA. Grivas P, et al. Eur Urol Oncol. 2023 Dec 27:S2588-9311(23)00288-2. doi: 10.1016/j.euo.2023.11.022. Online ahead of print. Eur Urol Oncol. 2023. PMID: 38155060
66 results